We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seems even chart experts can disagree this one looks positive
https://uk.tradingview.com/chart/AVCT/TtE3oQOF-AVCT-Watch-closely/
Anyway Covid affimers will be our golden eggs " Affimer® reagents are ideal tools for use in diagnostic test development, due to being highly specific, reproducible, stable, and easy to manufacture at scale." Healthy net profit margins per every affimer used - incremental cash into AVCT coffers ,
Partners pay for other LFT components .
https://avacta.com/diagnostics/affimer-technology/
https://avacta.com/diagnostics/key-benefits/
If he'd stuck to TA he may have continued to fool some of us but when he starts pontificating about a company that most of us know much better than he does...……….
case closed for me.
In @ 2.44 out @ 2.495 Bottomzup?
310p, which was based on a 70% ***probability*** of a successful launch.
with further news of the commercial rollout/roadmap ***expected*** at its upcoming results.
Hope words! People doing their precious research read past words like this.
My research is focused on how the stock market works, which often means reading what they are not saying, as well as what they are saying.
Thanks for sharing MR.Spacetomato
finnCap also mentioned "unchanged for the time being (310p, which was based on a 70% probability of a successful launch) and will reassess after its FY 2020 results on 22 April"
-------------------
"Avacta (AVCT): Corp Positive SARS-CoV-2 antigen test data
Avacta announced that it expects to CE mark its AffiDX® SARS-CoV-2 antigen lateral flow test (LFT) in early May following the release of positive clinical validation data, which indicate the test to have a 98.0% sensitivity and 99.0% specificity, based on 98 positive and 102 negative samples. These data were generated across a range of infectiousness; from low to higher viral load samples, with 100% sensitivity generated in a subset of patients deemed to be infectious
(Ct<27) and with the LFT also demonstrating better clinical sensitivity than two leading (currently undisclosed), commercially available LFTs. Avacta looks to be increasingly well positioned to successfully commercialise this test, with further news of the commercial rollout/roadmap expected at its upcoming results. We leave our rNPV target valuation
unchanged for the time being (310p, which was based on a 70% probability of a successful launch) and will reassess after its FY 2020 results on 22 April"
The tone of this note really is encouraging
'With demand for LFTs expected to remain high across Europe, we look forward to news of first orders in the coming months.'
Plus 1
GLA
Positive clinical validation of AffiDX® SARS-CoV-2 rapid antigen lateral flow
test. The study, carried out at a single site in Europe, tested 98 positive samples and
102 negative samples as confirmed by PCR testing. AffiDX SARS-CoV-2 antigen
lateral flow test identified 96/98 of these correctly as positive with a 20-minute read
time, resulting in a clinical sensitivity of 98.0%.
This included 31 samples with Ct<26;
65 with Ct 26-30 and 2 with Ct 30-31. The LFT demonstrated 100% sensitivity for
identifying infectious individuals with a PCT Ct<27, a level considered by many
virologists to be the cutoff for infectiousness.
Ct or cycle time indicates the number of
cycles of amplification required before the virus gene can be detected by PCR – the
higher the Ct value the lower the viral load and less infectious. The test correctly
identified 101/102 as negative, giving a clinical specificity of 99.0%.
Next steps – CE marking in early May. These data will be combined with stability
and other performance data from ongoing studies from its manufacturing partner,
Global Access Diagnostics, to finalise the technical file for CE marking the AffiDX
SARS-CoV-2 antigen lateral flow test for professional use. Avacta expects CE mark
in early May enabling it to begin commercial roll-out in Europe immediately thereafter.
Our thoughts. These data confirm that Avacta has an LFT with high sensitivity and
arguably superior performance to leading competitor LFTs, which should satisfy the
UK government’s drive for increased lateral flow testing, as well as comply with the
broader EU Commission directive for Member States to use LFTs with sensitivity =
80% and specificity = 97%. With demand for LFTs expected to remain high across
Europe, we look forward to news of first orders in the coming months.
https://www.finncap.com/research-portal?#/portal/finncap/research/8_27559